Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Inc. dropped 0.4% to $467.98 after the biotech company posted lower income in the fourth quarter ending in December.
Revenue increased to $2.91 billion from $2.52 billion, net income dropped to $913.0 million from $968.8 million, and earnings per diluted share fell to $3.50 from $3.71 a year ago.
Revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO, a prescription medicine used for cystic fibrosis treatment.
For fiscal 2025, the company estimated revenue between $11.75 billion and $12.0 billion, compared to $11.02 billion in 2024.
Feb 11, 2025 - Vertex Pharmaceuticals edged up 0.6% to $400.0 after the company agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, or about $65 per share.
Alpine Immune soared 36% to $64.21.
Apr 11, 2024
| Year | Mar | Jun | Sep | Dec | Annual | |
|---|---|---|---|---|---|---|
| 2023 | 2.69 | 3.52 | 3.97 | - | - | |
| 2022 | 2.96 | 3.13 | 3.59 | 3.14 | 12.82 | |
| 2021 | 2.49 | 0.26 | 3.28 | 2.98 | 9.01 | |
| 2020 | 2.29 | 3.18 | 2.53 | 2.29 | 10.29 | |
| 2019 | 1.03 | 1.03 | 0.22 | 2.23 | 4.51 | |
| 2018 | 0.81 | 0.8 | 0.5 | 5.98 | 8.09 | |
| 2017 | 0.13 | 0.10 | 0.24 | 0.32 | 0.79 | |
| 2016 | 0.13 | 0.01 | 0.09 | 0.13 | 0.36 | |
| 2015 | 0.86 | 0.80 | 0.40 | 0.02 | 2.08 | |
| 2014 | -1.00 | -0.68 | -0.72 | -0.74 | -3.14 | |
| 2013 | -1.43 | -0.26 | -0.54 | 0.25 | -1.98 | |
| 2012 | 0.43 | -0.31 | -0.27 | -0.35 | -0.5 | |
| 2011 | -0.87 | -0.85 | 1.02 | 0.84 | 0.14 | |
| 2010 | -0.83 | -1.00 | -1.04 | -0.90 | -3.77 | |
| 2009 | -1.04 | -0.99 | -0.84 | -0.84 | -3.71 | |
| 2008 | -0.72 | -0.66 | -0.93 | -0.96 | -3.27 | |
| 2007 | -0.64 | -0.91 | -0.82 | -0.66 | -3.03 | |
| 2006 | -0.47 | -0.72 | -0.46 | -0.18 | -1.83 | |
| 2005 | -0.56 | -0.50 | -0.84 | -0.38 | -2.28 |